Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 9/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251983 | 0.85 | KDR (0.43) | KDRCSNK1DCSNK1EMETAURKA | |
| SCHEMBL5955305 | 0.85 | KDR (0.40) | KDRCSNK1DCSNK1EMETAURKA | |
| SCHEMBL5955584 | 0.85 | KDR (0.41) | KDRCSNK1DCSNK1EMETAURKA | |
| SCHEMBL5954869 | 0.84 | KDR (0.48) | KDRCSNK1DCSNK1EMETAURKA | |
| SCHEMBL3397327 | 0.84 | KDR (0.44) | KDRCSNK1DCSNK1EMET | |
| SCHEMBL5954859 | 0.84 | KDR (0.44) | KDRCSNK1DCSNK1EMETPDGFRB | |
| SCHEMBL5955328 | 0.84 | KDR (0.41) | KDRCSNK1DCSNK1EMET | |
| SCHEMBL5955024 | 0.84 | KDR (0.44) | KDRCSNK1DCSNK1EMETAURKA | |
| SCHEMBL5954382 | 0.84 | KDR (0.42) | KDRCSNK1DCSNK1EMET | |
| SCHEMBL5955019 | 0.83 | KDR (0.40) | KDRCSNK1DCSNK1EMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | KDR 1387/4885CSNK1D 225/4885CSNK1E 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.